Making Pig-to-Human Transplantation a Clinical Reality with CRISPR Genome Editing
Xenotransplantation is a promising strategy to address the shortage of organs for human transplantation. Concerns about pig-to-human immunological compatibility and the risk of cross-species transmission of porcine endogenous retroviruses (PERVs) have impeded the clinical application of this approach.
Using CRISPR-Cas9, we inactivated all the PERVs in a porcine primary cell line and generated PERV-inactivated pigs via somatic cell nuclear transfer. Our study highlights the value of PERV inactivation to prevent cross-species viral transmission and demonstrates the successful production of PERV-inactivated animals to address safety concerns in clinical xenotransplantation. Using our genome editing platform, we are creating pigs with advanced immunological modifications to address immunological and functional compatibility issues.